Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

This study has been terminated.
Sponsor:
Information provided by:
Anza Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00585845
First received: December 22, 2007
Last updated: February 19, 2009
Last verified: February 2009
  Purpose

This clinical trial will evaluate the safety and tolerability of CRS 207 an investigational product that is a weakened form (attenuated) of Listeria monocytogenes, a type of bacteria that is commonly found in the environment. CRS-207 has been altered in the lab to reduce its ability to cause disease, while maintaining stimulation of the immune system. CRS 207 has also been genetically modified with recombinant DNA to release an antigen called Mesothelin. Because CRS 207 stimulates an immune response to Mesothelin and Mesothelin may be present at higher levels on tumor cells than on normal cells, this clinical trial will also examine if CRS 207 boosts the immune system in a way that targets certain types of cancer.

The purpose of this first clinical trial with CRS-207 is to identify an appropriate dose of the investigation agent for later clinical studies and to explore safety when given to consenting adults with advanced cancer of the ovary or pancreas, non-small cell lung cancer, or advanced malignant epithelial mesothelioma. Immunological response to CRS-207 and tumor status of study participants will also be measured. Patients who choose to enter the study must meet all study entry criteria and must have previously failed standard treatment for their cancer. Qualifying study patients will be assigned to receive one of several dose levels of CRS-207. Each patient may receive up to 4 intravenous administrations (21 days apart) of CRS-207 at their assigned dose level.


Condition Intervention Phase
Malignant Epithelial Mesothelioma
Adenocarcinoma of the Pancreas
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma of the Ovaries
Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Escalation, Multiple Dose Study of the Safety, Tolerability, and Immune Response of CRS-207 in Adult Subjects With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment

Resource links provided by NLM:


Further study details as provided by Anza Therapeutics, Inc.:

Primary Outcome Measures:
  • Dose-limiting toxicities related to the investigational agent [ Time Frame: 28 days after first dose ] [ Designated as safety issue: Yes ]

Enrollment: 17
Study Start Date: December 2007
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CRS-207 Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin
2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.

Detailed Description:

Patients who consent to participate in the study will be evaluated for eligibility according to their medical history, physical examination, blood testing, and computed tomography (CT) scan of thorax, abdomen, and pelvis. Those patients who qualify for the study will receive up to 4 intravenous doses of CRS-207, 21 days apart. After each infusion, they will be monitored overnight in an in-patient facility, including collection of blood specimens. Study participants will return after each infusion for outpatient follow-up visits for further blood tests and additional monitoring of safety and immune response to CRS-207. Participants will have repeat CT scans to measure tumor size after the 2nd dose and again after the 4th dose. On Day 91 participants will be discharged from the study. All study participants will be eligible to participate in a long-term follow-up study with a visit 6 months after the final dose of CRS-207 and annually thereafter for evaluation of disease progression, survival, and potential long-term toxicity of CRS 207.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Documented malignant epithelial mesothelioma, cancer of the pancreas or ovaries or non-small-cell lung cancer (NSCLC) and who have failed (or are not candidates for) standard therapy
  2. ECOG Performance Status of 0 to 1, or Karnofsky Performance Status (KPS) of 80-100%
  3. Adequate organ function as defined by study-specified laboratory tests
  4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug
  5. Signed informed consent form
  6. Willing and able to comply with study procedures

Exclusion Criteria:

  1. History of infection with Listeria, prior vaccination with a listeria-based vaccine, or a positive fecal culture of Listeria at screening
  2. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions
  3. Allergy to penicillin or yeast or other component of the study drug product (e.g., glycerol)
  4. Clinical metabolic or laboratory abnormalities defined as Grade 3 or 4 of the National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0
  5. Artificial (prosthetic) joint or other artificial implant or devices that cannot be easily removed
  6. Certain types of blood transfusions within 14 days prior to receiving study drug or a condition requiring regular blood transfusions more than twice per month
  7. Taking the following medications:

    • Anti-coagulation medications
    • Systemically active steroids for more than 2 days within 28 days prior to receiving study drug
    • More than 325 mg per day of aspirin
    • More than 2 g per day of acetaminophen
    • Systemic antibiotics within 14 days prior to receiving study drug
    • Another investigational product within 28 days prior to receiving study drug
  8. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug, or planned surgery requiring general anesthesia
  9. Infection with HIV, hepatitis B or C, or HTLV-1 (human t-lymphotropic virus type 1) at screening
  10. Pregnant or lactating, or close contact with pregnant women or newborn babies
  11. Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00585845

Locations
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
Baltimore, Maryland, United States, 21231
National Cancer Institute, NCI
Bethesda, Maryland, United States, 20892
United States, Pennsylvania
University of Pennsylvania Abramson Family Cancer Research Center
Philadelphia, Pennsylvania, United States, 19104
Israel
Hadassah Hebrew University Medical Center
Jerusalem, Israel, 91120
Sponsors and Collaborators
Anza Therapeutics, Inc.
Investigators
Study Director: Dung Thai Anza Therapeutics, Inc.
  More Information

No publications provided

Responsible Party: Dung Thai, Anza Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT00585845     History of Changes
Other Study ID Numbers: VAC07001
Study First Received: December 22, 2007
Last Updated: February 19, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Anza Therapeutics, Inc.:
Cancer
Ovarian cancer
Pancreatic cancer
Non-small cell lung cancer
Mesothelioma
Mesothelin
Immunotherapy

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma, Non-Small-Cell Lung
Mesothelioma
Neoplasms, Glandular and Epithelial
Neoplasms, Mesothelial
Ovarian Neoplasms
Adenoma
Adnexal Diseases
Bronchial Neoplasms
Carcinoma
Carcinoma, Bronchogenic
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Lung Diseases
Lung Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Ovarian Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Urogenital Neoplasms

ClinicalTrials.gov processed this record on November 25, 2014